POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB)
PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops.
Power3 Medical Products, Inc., a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced today that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, Power3's diagnostic test, and focused on Power3's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.
"In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease," said Dr. Ira L. Goldknopf, Power3's President and Chief Scientific Officer. "It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs."
"We are pleased that our blood tests specifically diagnose Alzheimer's in patients, both pre- and post-treatment," said Helen R. Park, MS, Chief Executive Officer of Power3, "and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii."
"We are within striking distance of realizing an Alzheimer's clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions," added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.
Power3 has filed several patent applications for its NuroPro® technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.
Yingli Green Energy Holding Co. Ltd. (NYSE:YGE) a leading solar energy company and one of the world's largest vertically integrated photovoltaic manufacturers, which markets its products under the brand "Yingli Solar," announced on October 28, 2010 that it plans to release its unaudited financial results for the third quarter ended September 30, 2010, before the U.S. market opens on Friday, November 19, 2010. The Company has scheduled a corresponding conference call and live webcast to discuss the results at 8:00 AM Eastern Standard Time (EST) on November 19, 2010, which corresponds to 9:00 PM Beijing/Hong Kong time the same day.
Yingli Green Energy Holding Company Limited, together with its subsidiaries, engages in the design, development, marketing, manufacture, installation, and sale of photovoltaic (PV) products in the People’s Republic of China and internationally.
Xerox Corp. (NYSE:XRX) announced the Xerox DocuMate® 3920, a new duplex color network scanner. Using either the flatbed or 50-page automatic document feeder (ADF), users can scan both sides of a document to e-mail, a network folder, fax recipient, FTP location or printer, through the large 7-inch, color LCD touch screen that clearly displays all operation modes. The screen is designed to be responsive to touch and the soft QWERTY keyboard makes data entry easy and fast. The Xerox DocuMate 3920 supports small to medium workgroups and offices with secure multi-user access and easy administration through an embedded form-based web page configuration and a standard Ethernet connection.
Xerox Corporation engages in the production and sale of document systems and services for businesses. It offers a range of color, and black-and-white multifunction devices; and printers, copier fax products, and document related software solutions.
BlackRock Kelso Capital Corporation (NasdaqGS:BKCC) announced that it has priced its public offering of 6 million shares of its common stock at an offering price of $11.95 per share, raising $71.7 million of gross proceeds. The Company has granted the underwriters an option to purchase up to an additional 900 thousand shares to cover over-allotments, if any. The offering is subject to customary closing conditions and is expected to close on October 22, 2010. The Company expects to use the net proceeds of this offering to make investments in portfolio companies, repay indebtedness owed under its credit facility, and for general corporate purposes.
lackRock Kelso Capital Corporation is a private equity firm specializing in investments in middle market companies. The firm invests in all industries. It prefers to invest between $10 million and $50 million and can invest more or less in companies with EBITDA or operating cash flow between $10 million and $50 million.
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).